Skip to main content
. 2016 Feb 24;7(13):16479–16489. doi: 10.18632/oncotarget.7660

Figure 7. Schematic illustration of how CVV can kill colon cancer cells by overcoming SCC issues.

Figure 7

The CVV has enhanced cancer-favoring selectivity and cytotoxicity, thereby enabling it to successfully override drug resistance and/or other limitations of currently developed targeted therapies in terms of killing colon cancer cells, regardless of the presence of SCCs, because of its cancer-favoring characteristics and the different cytotoxic pathway used to kill cancer cells.